Gilead Sciences, Inc. filed a Schedule 13G with the SEC on November 5, 2026, disclosing beneficial ownership of 2,879,996 shares of Aspen Neuroscience, Inc. common stock, representing 9.9% of the class, based on an event date of October 30, 2026.

Key Highlights

  • Reporting person: Gilead Sciences, Inc., a Delaware corporation, filed the disclosure.
  • Shares beneficially owned: 2,879,996 shares of Aspen Neuroscience common stock, par value $0.0001 per share.
  • Percent of class: 9.9% of Aspen Neuroscience's outstanding common stock.
  • Voting and dispositive power: Gilead Sciences reported sole voting power and sole dispositive power over all 2,879,996 shares, with zero shared voting or dispositive power.
  • Triggering event date: October 30, 2026, is cited as the date of the event requiring the filing.
  • Certifying officer: Andrew D. Dickinson, Executive Vice President and Chief Financial Officer, signed the filing on November 5, 2026.

Gilead Sciences Reports Passive Beneficial Ownership Position in Aspen Neuroscience

According to the Schedule 13G filing, Gilead Sciences, Inc., headquartered at 333 Lakeside Drive, Foster City, California 94404, reported beneficial ownership of 2,879,996 shares of Aspen Neuroscience, Inc. common stock. The shares carry a par value of $0.0001 per share and are identified by CUSIP number 044933109. Aspen Neuroscience is listed with principal executive offices at 10835 Road to the Cure, Suite 100, San Diego, CA 92121.

The filing indicates that Gilead Sciences holds sole voting power and sole dispositive power over all 2,879,996 shares, with no shared voting or dispositive power reported. The aggregate beneficial ownership represents 9.9% of Aspen Neuroscience's class of common stock, as disclosed in the filing. The company checked none of the institutional categories listed under Item 3, indicating the applicable filing rule basis was not designated as one of those enumerated institutional types.

The filing includes a certification, as required, stating that "the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11." Andrew D. Dickinson, Executive Vice President and Chief Financial Officer of Gilead Sciences, signed the statement on November 5, 2026.

What Was Disclosed

Gilead Sciences, Inc. filed a Schedule 13G disclosing beneficial ownership of 2,879,996 shares, or 9.9%, of Aspen Neuroscience, Inc. common stock, with the triggering event dated October 30, 2026, and the filing signed on November 5, 2026.